Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ANVS Annovis Bio, Inc.

Not Yet Opened 12-20 16:00:00 EST

4.37

-0.03

-0.68%

盘后4.37

+0.000.00%

19:48 EST

High4.53	Low4.30	Vol330.16K
Open4.46	D1 Closing4.40	Amplitude5.23%
Mkt Cap60.29M	Tradable Cap47.99M	Total Shares13.80M
T/O1.45M	T/O Rate3.01%	Tradable Shares10.98M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ANVS","market":"US","secType":"STK","nameCN":"Annovis Bio, Inc.","latestPrice":4.37,"timestamp":1734728400000,"preClose":4.4,"halted":0,"volume":330156,"hourTrading":{"tag":"盘后","latestPrice":4.37,"preClose":4.37,"latestTime":"19:48 EST","volume":737,"amount":3206.07,"timestamp":1734742092646},"delay":0,"floatShares":10982300,"shares":13797242,"eps":-3.972968,"marketStatus":"Not Yet Opened","change":-0.03,"latestTime":"12-20 16:00:00 EST","open":4.46,"high":4.53,"low":4.3,"amount":1448012.150399,"amplitude":0.052273,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.972968,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":0,"adr":0,"listingDate":1580274000000,"exchange":"NYSE","adjPreClose":4.4,"preHourTrading":{"tag":"盘前","latestPrice":4.438,"preClose":4.4,"latestTime":"09:29 EST","volume":1450,"amount":6374.78,"timestamp":1734704951988},"postHourTrading":{"tag":"盘后","latestPrice":4.37,"preClose":4.37,"latestTime":"19:48 EST","volume":737,"amount":3206.07,"timestamp":1734742092646},"volumeRatio":0.9153699512498228,"impliedVol":2.2942,"impliedVolPercentile":0.496},"requestUrl":"/m/hq/s/ANVS/tweets","defaultTab":"tweets","newsList":[{"id":"2490918858","title":"BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, Tesla, ADM","url":"https://stock-news.laohu8.com/highlight/detail?id=2490918858","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490918858?lang=en_us&edition=fundamental","pubTime":"2024-12-12 02:54","pubTimestamp":1733943246,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, Tesla, ADMEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nL4N3NC11X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEM","CADL","SIRI","SFIX","LU0198837287.USD","GTLS","WMB","DNUT","FLNC","XOM","LOAR","ANAB","PDCO","TSLA","VRA","QTTB","IBRX","LU0082616367.USD","LU1804176565.USD","LU1861559042.SGD","LU1116320737.USD","RCKT","EQT","EGP","ANVS","LU2458330243.SGD","FIGS","ACI","NTNX","MNKD","BK4212","BK4202","ADM","CNX","RLAY","IE00BJTD4N35.SGD","USAW.SI","AVGO","AMZN","CLRB","LU0823421333.USD","PLAY","TSYW.SI","LU0312595415.SGD","AZO","MDLZ","CGON","LU1992135399.USD","PLD"],"gpt_icon":1},{"id":"2490850997","title":"BUZZ-U.S. STOCKS ON THE MOVE-Exxon Mobil, Mondelez International, Macy's","url":"https://stock-news.laohu8.com/highlight/detail?id=2490850997","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490850997?lang=en_us&edition=fundamental","pubTime":"2024-12-11 22:11","pubTimestamp":1733926284,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Exxon Mobil, Mondelez International, Macy'sEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call ne","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nL4N3NC0P7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLNC","PLAY","QTTB","BK4596","CADL","IBRX","CLRB","BK4175","CGON","M","PDCO","RLAY","LU1878469433.USD","PLD","SG9999015358.SGD","FIGS","MDLZ","MNKD","LU1582986433.USD","RJF","LU1481011671.HKD","LU1093756168.USD","LU0162691827.USD","ALK","OMC","LU1839511570.USD","LU0130517989.USD","EGP","LU0792757196.USD","DNUT","LU0477156797.USD","GEV","LU0949170772.SGD","LU1732799900.SGD","LU2264538146.SGD","LUV","SFIX","LU0068578508.USD","SG9999002232.USD","GM","SG9999014567.USD","SIRI","SG9999001440.SGD","RCKT","BK4182","LU0787776722.HKD","ANVS","XOM","IE00B3CCJ963.GBP"],"gpt_icon":1},{"id":"2490856620","title":"BUZZ-Annovis Bio falls on planned $50 mln share sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2490856620","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490856620?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:32","pubTimestamp":1733920336,"startTime":"0","endTime":"0","summary":"BUZZ-Annovis Bio falls on planned $50 mln share sale** Drug developer Annovis Bio's ANVS.N shares fall 4.6% to $5.40 premarket** ANVS files for up to $50 mln \"at-the-market\" stock sale agreement to be handled by Oppenheimer ** Co plans to use the proceeds for general corporate purposes, including the development of its lead experimental drug buntanetap       ** ANVS set to host its year-end investor webcast late Wednesday    ** ANVS has 13.8 mln outstanding shares and $78 mln market capitalization - LSEG data    ** As of last close, ANVS shares down 69.7% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nL4N3NC0UN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2490302448","title":"BRIEF-Annovis Bio Enters Equity Distribution Agreement With Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2490302448","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490302448?lang=en_us&edition=fundamental","pubTime":"2024-12-11 19:31","pubTimestamp":1733916679,"startTime":"0","endTime":"0","summary":"BRIEF-Annovis Bio Enters Equity Distribution Agreement With OppenheimerDec 11  - Annovis Bio Inc ANVS.N:ANNOVIS BIO INC - ENTERS EQUITY DISTRIBUTION AGREEMENT WITH OPPENHEIMERANNOVIS BIO INC - TO OFFER UP TO $50 MILLION IN COMMON STOCKFurther company coverage: ANVS.N ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nFWN3NB1U0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2490883741","title":"Annovis Bio Inc - to Offer up to $50 Million in Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2490883741","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490883741?lang=en_us&edition=fundamental","pubTime":"2024-12-11 19:12","pubTimestamp":1733915544,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nFWN3NB1U0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2490837497","title":"Annovis Bio Inc - Enters Equity Distribution Agreement With Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2490837497","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490837497?lang=en_us&edition=fundamental","pubTime":"2024-12-11 19:12","pubTimestamp":1733915544,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nFWN3NB1U0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2490163083","title":"Annovis Bio Inc - Appoints William Fricker as Interim CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2490163083","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490163083?lang=en_us&edition=fundamental","pubTime":"2024-12-10 05:17","pubTimestamp":1733779028,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nFWN3NA1FQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2489246966","title":"Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace","url":"https://stock-news.laohu8.com/highlight/detail?id=2489246966","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489246966?lang=en_us&edition=fundamental","pubTime":"2024-12-05 21:30","pubTimestamp":1733405400,"startTime":"0","endTime":"0","summary":"This TMP episode highlights an exclusive interview with Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio. Conducted by host Jane King, the discussion focused on Annovis’ groundbreaking drug development for neurodegenerative diseases such as Alzheimer’s and Parkinson’s.“We think of the patients, but we should also think of the caregivers because the caregivers are very much affected by neurodegeneration too,” Dr. Maccecchini shared during the interview. She also elaborated on the next-phase clinical trials for Annovis’ drug, which targets the toxic proteins responsible for nerve cell damage in both diseases.TMP, filmed at prestigious venues like the New York Stock Exchange and NASDAQ MarketSite, is renowned for delivering compelling interviews with C-suite executives, targeting investors, financial professionals, and industry stakeholders. Dr. Maccecchini remarked, “It was an incredible experience to speak on TMP and share insights about our work at Annovis. I encourage","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bYQvcxcJKxZ9Naw2pZUDDw--~B/aD03MTg7dz0xMjc2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/a114a7e9ffad10fc4632c57f21bec6a2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bYQvcxcJKxZ9Naw2pZUDDw--~B/aD03MTg7dz0xMjc2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/a114a7e9ffad10fc4632c57f21bec6a2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/annovis-ceo-showcases-groundbreaking-advances-133000812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GRO","BK4211","DBP","BK4139","ANVS","TMP"],"gpt_icon":0},{"id":"2486901089","title":"Annovis to Host Year-End Investor Webcast on December 11, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2486901089","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486901089?lang=en_us&edition=fundamental","pubTime":"2024-11-25 21:00","pubTimestamp":1732539600,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Nov.  25, 2024  (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/25/2986627/0/en/Annovis-to-Host-Year-End-Investor-Webcast-on-December-11-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4588","LU0823038988.USD","IE00BYTNYM70.SGD","BK4181","SG9999004220.SGD","LU0066902890.USD","LU0143863198.USD","BK4585","LU1102505762.USD","LU0143863784.USD","LU0164881194.USD","LU0823039010.USD","LU0531971678.HKD","BK4207","LU1868837722.USD","BK4535","IBN","LU1868837565.USD","IE00B7N09G41.SGD","LU0251143458.SGD","BK4139","IE00B0JY6M65.USD","GRO","ANVS","LU0828237940.HKD","BK4218","HST","LU0181495838.USD","LU1868838027.USD","BK4523","LU1102505929.USD","LU0264410563.USD"],"gpt_icon":0},{"id":"2483551327","title":"Strategic Buy Rating on Annovis Bio Amid Regulatory Alignment and Growth Potential in Alzheimer’s Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2483551327","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483551327?lang=en_us&edition=fundamental","pubTime":"2024-11-15 20:15","pubTimestamp":1731672911,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Sumant Kulkarni has maintained their bullish stance on ANVS stock, giving a Buy rating on November 11. Sumant Kulkarni ha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/strategic-buy-rating-on-annovis-bio-amid-regulatory-alignment-and-growth-potential-in-alzheimers-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/strategic-buy-rating-on-annovis-bio-amid-regulatory-alignment-and-growth-potential-in-alzheimers-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANVS"],"gpt_icon":0},{"id":"2482270152","title":"Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2482270152","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482270152?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:00","pubTimestamp":1731416400,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Nov.  12, 2024   -- via IBN – Annovis Bio Inc.  , a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease  and Parkinson’s disease , today announced that its President and CEO, Maria Maccecchini, Ph.D., has been invited to speak at the National Institute on Aging  workshop, “Dementia with Lewy Bodies: Filling the Gaps in Translational and Clinical Research.” This prestigious workshop, sponsored by the NIA and the National Institute of Neurological Disorders and Stroke , will be held on November 12-13, 2024, and accessible online for registered attendees. Presentation Details: Title: One Drug, Dual Effect: Buntanetap Improves Cognitive and Motor Functions, Benefiting Alzheimer's and Parkinson's Patients. A Potential Path for Lewy Body Dementia?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/12/2979097/0/en/Annovis-Invited-to-Present-at-National-Institute-on-Aging-Workshop-on-Dementia-with-Lewy-Bodies-DLB.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BYTNYM70.SGD","LU0205193047.USD","LU1102505762.USD","LU1868837565.USD","LU0828237940.HKD","GRO","LU0143863198.USD","PD","BK4548","LU0531971678.HKD","LU0143863784.USD","ANVS","LU0251143458.SGD","LU1102505929.USD","BK4588","LU0240877869.USD","LU0240878834.USD","LU0823039010.USD","BK4023","LU1868837722.USD","BK4585","LU0264410563.USD","BK4139","BK4207","DLB","LU0164881194.USD","NHLD","LU0205194284.USD","BK4535","LU1169590202.USD","BK4097","LU1868838027.USD","LU0345774631.USD","BK4523","LU0181495838.USD","LU0823038988.USD","LU0345774391.USD","IE00B0JY6M65.USD","LU0066902890.USD","IBN","LU0348723411.USD","IE00B7N09G41.SGD","SG9999004220.SGD","LU1169589451.USD"],"gpt_icon":0},{"id":"2482781569","title":"Annovis Bio GAAP EPS of -$0.97 misses by $0.58","url":"https://stock-news.laohu8.com/highlight/detail?id=2482781569","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482781569?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:14","pubTimestamp":1731330862,"startTime":"0","endTime":"0","summary":"Annovis Bio press release (NYSE:ANVS): Q3 GAAP EPS of -$0.97  misses by $0.58. As of November 8, 2024, Annovis had cash and cash equivalents of $13.6 million. The company has an adequate runway for all Phase 3 preparatory studies and for entering the pivotal","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4274126-annovis-bio-gaap-eps-of-0_97-misses-0_58","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["ANVS"],"gpt_icon":0},{"id":"2482789853","title":"Annovis Bio Q3 EPS $(0.97) Misses $(0.38) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2482789853","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482789853?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:06","pubTimestamp":1731330399,"startTime":"0","endTime":"0","summary":"Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.38) by 155.26 percent. This is a 40.49 percent increase over losses of $(1.63) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41876835/annovis-bio-q3-eps-0-97-misses-0-38-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Annovis Bio Q3 EPS $(0.97) Misses $(0.38) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS"],"gpt_icon":0},{"id":"2482485786","title":"Annovis Bio Reports Third Quarter Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2482485786","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482485786?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:00","pubTimestamp":1731330003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUA7XBPYD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2482786063","title":"Annovis Bio Reports Third Quarter Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2482786063","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482786063?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:00","pubTimestamp":1731330000,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Nov.  11, 2024  (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (\"Annovis\" or the \"Company\"), a clinical-stage drug platform company developing novel therapies for neurodege","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/11/2978272/0/en/Annovis-Bio-Reports-Third-Quarter-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0164881194.USD","LU0251143458.SGD","BK4023","BK4523","BK4588","LU0066902890.USD","LU1868837565.USD","IE00B0JY6M65.USD","LU0828237940.HKD","LU0143863198.USD","LU0143863784.USD","BK4548","BK4535","LU1868838027.USD","BK4585","LU0823039010.USD","BK4207","LU1169589451.USD","LU0531971678.HKD","PD","IE00B7N09G41.SGD","SG9999004220.SGD","BK4139","IE00BYTNYM70.SGD","LU0823038988.USD","GRO","LU1102505762.USD","ANVS","IBN","LU0264410563.USD","LU1868837722.USD","LU1102505929.USD","LU0181495838.USD","LU1169590202.USD"],"gpt_icon":0},{"id":"2482578558","title":"Annovis Bio Price Target Maintained With a $30.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2482578558","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482578558?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:39","pubTimestamp":1731328740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANVS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2024 07:39 ET (12:39 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS"],"gpt_icon":0},{"id":"2482805447","title":"Annovis Bio Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2482805447","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482805447?lang=en_us&edition=fundamental","pubTime":"2024-11-09 20:26","pubTimestamp":1731155169,"startTime":"0","endTime":"0","summary":"* Annovis Bio Inc    reported a quarterly adjusted loss of 97 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.63.  The ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Annovis Bio Inc reports results for the quarter ended September 30 - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS"],"gpt_icon":0},{"id":"2481904837","title":"Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist","url":"https://stock-news.laohu8.com/highlight/detail?id=2481904837","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481904837?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984400,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Nov. 07, 2024  -- via IBN --Annovis Bio Inc.  , a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease  and Parkinson’s disease , today announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson will be responsible for medical, ethical, and scientific quality and rigor in the initiation, conduct, reporting, and successful completion of Annovis’ clinical trials.\"We are thrilled to welcome Matthew Peterson to our team,\" said Cheng Fang, Ph.D., Senior Vice President, Research and Development, at Annovis. \"Dr. Peterson brings an impressive track record in clinical research and a passion for improving patient outcomes, joining us at a crucial moment as we are approaching initiation of pivotal Phase 3 studies.”\"I am excited to join Annovis and to work alongside such a dedicated team at this pivotal moment for the company,\" said Dr. Peterson. \"I look forward","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/nFPIV6UEv5MtRZH7nCVaFQ--~B/aD0xNTg7dz0zMjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/9fc709677795ec8aacefdbb92bf7c00b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/nFPIV6UEv5MtRZH7nCVaFQ--~B/aD0xNTg7dz0zMjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/9fc709677795ec8aacefdbb92bf7c00b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/annovis-bio-appoints-matthew-peterson-130000124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B0JY6M65.USD","BK4139","BK4523","LU1102505762.USD","LU0823039010.USD","LU0066902890.USD","LU0143863784.USD","LU0143863198.USD","BK4207","LU0823038988.USD","LU1868838027.USD","LU0531971678.HKD","PD","SG9999004220.SGD","LU1169590202.USD","LU1868837722.USD","BK4535","LU0828237940.HKD","IE00BYTNYM70.SGD","LU0181495838.USD","IBN","BK4023","LU0264410563.USD","IE00B7N09G41.SGD","ANVS","BK4588","LU1102505929.USD","LU1868837565.USD","BK4548","LU1169589451.USD","LU0164881194.USD","BK4585","LU0251143458.SGD"],"gpt_icon":0},{"id":"2480158002","title":"Annovis Bio Inc    expected to post a loss of 53 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2480158002","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480158002?lang=en_us&edition=fundamental","pubTime":"2024-11-04 23:48","pubTimestamp":1730735301,"startTime":"0","endTime":"0","summary":"* Annovis Bio Inc     is expected to show no change in quarterly revenue when it reports  results on November 6 (estimated) for the period ending January 1 0001   *    * LSEG's mean analyst estimate f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Annovis Bio Inc    expected to post a loss of 53 cents a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS"],"gpt_icon":0},{"id":"2479051088","title":"Ibn Announces Latest Episode of the Biomedwire Podcast Featuring DR. Maria Maccecchini, CEO of Annovis Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2479051088","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479051088?lang=en_us&edition=fundamental","pubTime":"2024-10-31 20:00","pubTimestamp":1730376003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nTUA7JP7BJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.annovisbio.com","stockEarnings":[{"period":"1week","weight":-0.177},{"period":"1month","weight":-0.3318},{"period":"3month","weight":-0.4841},{"period":"6month","weight":-0.2643},{"period":"1year","weight":-0.6133},{"period":"ytd","weight":-0.7663}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.001878},{"month":2,"riseRate":0.4,"avgChangeRate":0.208855},{"month":3,"riseRate":0.4,"avgChangeRate":-0.008916},{"month":4,"riseRate":0.2,"avgChangeRate":-0.160489},{"month":5,"riseRate":0.6,"avgChangeRate":0.247553},{"month":6,"riseRate":0.6,"avgChangeRate":0.216567},{"month":7,"riseRate":0.6,"avgChangeRate":0.066217},{"month":8,"riseRate":0.4,"avgChangeRate":-0.05366},{"month":9,"riseRate":0.4,"avgChangeRate":-0.049402},{"month":10,"riseRate":0.2,"avgChangeRate":-0.090551},{"month":11,"riseRate":0.6,"avgChangeRate":0.036162},{"month":12,"riseRate":0.4,"avgChangeRate":0.193455}],"exchange":"NYSE","name":"Annovis Bio, Inc.","nameEN":"Annovis Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Annovis Bio, Inc.,ANVS,Annovis Bio, Inc.股票,Annovis Bio, Inc.股票老虎,Annovis Bio, Inc.股票老虎国际,Annovis Bio, Inc.行情,Annovis Bio, Inc.股票行情,Annovis Bio, Inc.股价,Annovis Bio, Inc.股市,Annovis Bio, Inc.股票价格,Annovis Bio, Inc.股票交易,Annovis Bio, Inc.股票购买,Annovis Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction